SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Innova Biosciences brand, to support scalability and bulk production of antibodies.
Lightning-Link is an innovative technology that enables direct labeling of antibodies or proteins in as little as 20 minutes, for use in R&D applications, drug discovery and the development of diagnostic kits. Lightning-Link kits are the world’s fastest, easiest to use and most efficient method of labeling antibodies or proteins, requiring only 30 seconds hands-on time, and there are no separation steps involved, meaning 100% of materials are retained.
The increased manufacturing capability means the Company is now able to offer the Lightning-Link product range in volumes from 10µg to 100mg, in single reaction vials tested with Rabbit IgG in ELISA. For...
Alastair Carrington, VP Business Development & Marketing, Innova Biosciences, commented: “The ability to further support antibody manufacturers at both small and large scale, including those requiring bulk raw materials to work with historic standard operating procedures, provides the opportunity to reach new, high value markets. Access to Lightning-Link technology will enable manufacturers to dramatically increase their conjugate portfolios, whilst retaining batch-to-batch consistency.”
All raw materials used in Lightning-Link kits are manufactured from natural sources, grown in continuous microalgae culture, providing assurance of high quality purification with extreme quantum efficiency and excellent stability.